<DOC>
	<DOCNO>NCT00198289</DOCNO>
	<brief_summary>Patients least 7 year old stable Cystic Fibrosis Staphylococcus aureus Lungs enrol study receive one dose Aurexis® intravenously Study Day 1 , follow Study Day 57 . Aurexis humanize monoclonal antibody design combat Staphylococcus aureus . The purpose study assess safety pharmacokinetic profile ( concentration Aurexis blood sputum ) Aurexis . Additionally , certain test measurement conduct preliminarily determine Aurexis demonstrate benefit patient .</brief_summary>
	<brief_title>Aurexis® Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus Their Lungs</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female , age &gt; 7 year old Diagnosis CF evidence sweat chloride test and/or genetic mutation test Sputum SA CFUs &gt; 10,000 per mL Ability expectorate sputum Ability tolerate nasal lavage collection breath condensate Willing practice reliable birth control measure entire study period , subject childbearing potential Informed consent obtain subject legal guardian , assent appropriate Burkholderia cepacia sputum Subjects change treatment regimen CF past 6 week Subjects screen 6 week IV antibiotic completion Subjects screen 7 day oral antibiotic completion Received investigational drug within 30 day study entry Received immune globulin blood product within 30 day study entry History hypersensitivity immune globulin preparation Undergoing type dialysis expect start dialysis within 30 day Pregnant nursing female Considered unlikely comply study procedure return schedule posttreatment evaluation</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>lung</keyword>
</DOC>